|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RESULTS IHC of SSTR subtypes in the different cohorts showed SSTR2 staining intensity scores higher than SSTR5 in TSHoma, acromegaly and prolactinoma, whereas the expression of SSTR5 was stronger than SSTR2 in corticotropinoma and NFPA.
|
28434012 |
2017 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.
|
15994755 |
2005 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, studies using somatostatin (SRIF) analogs preferential for either the SRIF receptor 2 (SSTR2) or the SSTR5 subtype demonstrated a variable suppression of GH and PRL release from GH-secreting human adenomas.
|
10690891 |
2000 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Six of 9 somatotroph adenomas, 1 of 4 lactotroph adenomas and 1 of 2 thyrotroph adenomas also expressed SSTR5.
|
8866248 |
1996 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the SSTR5-preferring analog showed a slight additive effect when used in combination with SSTR2 preferential drugs at submaximal concentrations in octreotide partially sensitive adenomas.
|
11231991 |
2001 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No correlation between SSTR2 and SSTR5 genotypes, responsiveness to somatostatin therapy, and mRNA expression in the removed adenomas (n = 10) was found.
|
15914528 |
2005 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The intensity of SSTR5 expression and the granulation pattern of adenomas were of limited value for the prediction of Pasireotide-LAR effectiveness.
|
31518993 |
2019 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings demonstrated that TSH-secreting adenomas express sstr1, 2A, 3 and 5 mRNAs, predominantly sstr2A, and in addition to the expression of sstr2 mRNA, the expression level of sstr5 mRNA may be a factor affecting the tumor shrinkage by somatostatin analogues against TSH-secreting adenomas.
|
17420609 |
2007 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, SSTR5 was highly expressed in 10 of 11 GH-secreting adenomas and 1 prolactinoma.
|
7521350 |
1994 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We quantified the expression of SSTR2 and SSTR5 mRNA using a semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) in 19 human growth hormone (GH) -secreting adenomas.
|
11264647 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Somatostatin receptor type 5 (SSTR5) P335L is a hypofunctional, single nucleotide polymorphism of SSTR5 with implications in the diagnostics and therapy of pancreatic neuroendocrine neoplasms.
|
22136833 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cushing's disease (CD), SSTR5 is the most abundant receptor expressed and tumors show low SSTR2 density due to hypercortisolism-induced SSTR2 down-regulation.
|
24647046 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of the entire SSTR5 gene disclosed the variant c.142C>A (rs4988483" genes_norm="6755">p.L48M, rs4988483) in the heterozygous state in both blood and tumor, while no pathogenic mutations were noted in the MEN1, AIP, p27Kip1 and SSTR2 genes.
|
21744088 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hsp90, TGFBR1, IGF1R, and SSTR5 exhibited highest levels of immunohistochemical staining in the largest percents of tumors.
|
20385747 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IHC evaluation of tumor samples from two patients (a responder and a non-responder) revealed positive immunostaining for PRL and SSTR5 but not for other pituitary hormones or for SSTR2.
|
29948930 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SSTR1 to SSTR5 expression in PC tumors.
|
30657933 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, SSTR5 was increased in pancreatic and well-differentiated tumors.
|
28454229 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies to somatostatin receptors 2A (SSTR2A, UMB-1) and 5 (SSTR5, UMB-4) were reported to be highly reliable for immunohistochemical detection of these receptors in neuroendocrine neoplasms.
|
29180250 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SSTR5 mRNA was detected in two tumors from the responder, but not in one tumor that was resistant to OCT.
|
17159301 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of SSTR5 was detected in approximately one-third of tumour and normal tissue, but fewer than 13% of all tissues expressed SSTR1, 3 and 4.
|
9062398 |
1997 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found somatostatin receptor type 5 (SST5) expressed in 17 different ACTH-secreting tumors and SST2 detectable in 15 out of the 17 tissues.
|
30611770 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The patient with marked shrinkage of the tumor showed the highest expression of both sstr2 and sstr5 mRNAs among all the cases of pituitary adenoma.
|
17420609 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this retrospective study the SSTR5 gene in paired tumor and blood samples from 33 pancreatic adenocarcinoma patients using the Sanger method were sequenced.
|
21692047 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the protein expression of SSTR2, but not of SSTR5, is a valuable indicator in predicting biochemical and tumor size response to short-term SSA treatment in acromegalic patients.
|
28396686 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The observed positive correlation between SSTR5 expression and tumour size suggests that the use of SST analogues more specific to SSTR5 in the treatment of insulinomas deserves attention.
|
16601280 |
2006 |